Advances in Hematology / 2021 / Article / Tab 2 / Research Article
A Phase II Trial of Melphalan Based Reduced-Intensity Conditioning for Transplantation of T-Replete HLA-Haploidentical Peripheral Blood Stem Cells with Posttransplant Cyclophosphamide in Patients with Hematologic Malignancies Table 2 Patients’ characteristics in two groups.
valueflu/Mel flu/Cy/TBI N 25 61 Age, median (range) 57 (35, 68) 61 (22, 75) 0.10 Male sex 11 (44%) 32 (52%) 0.64 Diagnosis 0.08 AML 11 (44%) 13 (21%) ALL 4 (16%) 4 (7%) MDS/MPS/CML 6 (24%) 14 (23%) NHL/CLL/HD 3 (12%) 24 (39%) PCD 1 (4%) 2 (3%) Other 0 (0%) 4 (8%) Cell source <0.001 PBSC 25 (100%) 37 (61%) BM 0 (0%) 24 (39%) Patient CMV 0.38 Positive 18 (72%) 50 (82%) Negative 7 (28%) 11 (18%) ABO compatibility 0.32 Compatible 16 (64%) 33 (54%) Incompatible minor 2 (8%) 15 (25%) Incompatible minor and major 1 (4%) 2 (3%) Incompatible major 6 (24%) 11 (18%) DRI 0.06 Low 1 (4%) 7 (12%) Intermediate 13 (52%) 27 (45%) High/very high 11 (44%) 23 (38%) CMl 0.09 1–3 11 (44%) 39 (64%) 4–8 14 (56%) 22 (36%) Female donor male recipient 4 (16%) 8 (13%) 0.74